Healthcare

DataMEDS AI Reports $2.7 Million Third-Quarter Revenue and $2.72 Net Profit Per Share

DataMEDS AI reported third-quarter 2026 revenue of $2.7 million and net profit per share of $2.72, while outlining developments involving Corexa Pharmacy, Helomics and its Health Lives Here app.

Published:
Reading Time
3 min

DataMEDS AI, Inc. (NASDAQ:MEDS) reported third-quarter 2026 revenue of $2.7 million, compared with $1.8 million in the second quarter of 2026. The company said the increase was primarily linked to higher drug-dispensing activity at Corexa Pharmacy.

#Third-quarter financial results

For the quarter ended September 30, 2026, DataMEDS AI recorded a net operating profit of $10.535 million. That compares with a net operating loss of $34.318 million for the quarter ended September 30, 2025.

The company attributed the change largely to the extinguishment of debt and outstanding liabilities connected with litigation involving prior management. It also cited lower management compensation expenses and reduced general and administrative expenses.

Net profit per share was $2.72 based on 3.961 million weighted average shares outstanding. In the quarter ended September 30, 2025, the company reported a loss of $23.07 per share based on 1.488 million weighted average shares outstanding.

#Health Lives Here and Corexa Pharmacy

DataMEDS AI launched the Health Lives Here mobile application in partnership with the NFL Alumni Health marketing platform. The company said the app provides Corexa Pharmacy with a channel to reach customers for FDA-approved GLP-1 medications and Forzet™, a medical food for the dietary management of muscle loss associated with weight loss therapies.

The application incorporates DataMEDS AI’s EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform. Corexa Pharmacy provides dispensing and related pharmacy services, including distribution of products developed by Tollo Health.

#REBOOT licence and compounded peptides

In October 2026, DataMEDS AI obtained an exclusive licence to the REBOOT GLP-1 patient management platform and related intellectual property. The company said the licence covers patented, AI-assisted patient management services that it believes can support customer acquisition and long-term customer value.

Corexa Pharmacy also launched compounded peptides in November 2026 under the FDA’s Enforcement Discretion Policy published in the Federal Register on October 30, 2026. DataMEDS AI described the offering as an incremental revenue opportunity.

Compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. The company also identified compliance with the policy and state pharmacy laws as risks, including the possibility that the policy could be changed or withdrawn.

#Florida HMO memorandum

In November 2026, DataMEDS AI signed a non-binding memorandum of understanding with a Florida-based HMO to deploy the Health Lives Here app to its 25,000+ members. The company said the arrangement would provide an institutional customer base for its per-member-per-month model.

Definitive agreements are expected in the fourth quarter of 2026. However, DataMEDS AI stated that the memorandum is non-binding and that definitive agreements may not be executed on the expected timeline or at all.

#Helomics acquisition and diagnostic services

DataMEDS AI acquired Helomics Corporation in September 2026. Helomics is a Pittsburgh-based CLIA-certified cancer diagnostics laboratory focused on the ChemoFx® Assay, a proprietary chemotherapy-selection diagnostic test.

Humana’s South Carolina Medicaid coverage policy for the ChemoFx® Assay took effect on July 22, 2026. DataMEDS AI said the policy adds a proprietary revenue stream, while the laboratory’s 70,000+ primary tumor biopsies create drug discovery opportunities.

The company said it is expanding Helomics’ test menu to serve patient groups beyond cancer, particularly GLP-1 patients. It also identified the integration of Helomics, ChemoFx testing volumes and reimbursement as areas subject to uncertainty.

#Nasdaq compliance

DataMEDS AI said it regained full compliance with Nasdaq listing standards, including the net equity requirement, on October 19, 2026.

The company cautioned that its forward-looking statements are based on management’s current expectations and are not predictions of actual performance. It identified additional risks involving demand for GLP-1 medications and Forzet™, healthcare-law compliance, liquidity, capital resources and the ability to fund operations.

#Key Takeaways

  • DataMEDS AI reported $2.7 million in third-quarter 2026 revenue, up 50% from $1.8 million in the second quarter of 2026.
  • Net operating profit was $10.535 million, while net profit per share was $2.72 based on 3.961 million weighted average shares outstanding.
  • Corexa Pharmacy launched compounded peptides, which are not FDA-approved or evaluated by the FDA for safety or efficacy.
  • The company signed a non-binding memorandum with a Florida-based HMO covering potential app deployment to 25,000+ members.
  • DataMEDS AI said it acquired Helomics and regained full compliance with Nasdaq listing standards.

Original source: Read original article

Frequently Asked Questions